BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Infectio Diagnostic Inc. Concludes New Agreements To Accelerate Market Penetration Of Its Real Time Diagnostic Products


10/19/2005 5:10:18 PM

QUEBEC CITY, Nov. 6 /PRNewswire/ -- Infectio Diagnostic Inc. (IDI), and Cepheid have just concluded new agreements to better serve their respective interests. At the same time they are terminating the current ARIDIA joint venture. These new agreements will enable IDI and Cepheid increasing the synergy between their technologies and providing each company greater flexibility in building and operating their businesses.

The summary of these new agreements is : - IDI receives worldwide rights to distribute Cepheid's Smart Cycler(R) for use with IDI's assays. - IDI will be able to independently develop its own menu of assays on the real time PCR platform, the Smart Cycler(R), manufactured and supplied by Cepheid. - IDI receives worldwide rights to sell the complete system through its own distribution network. - Cepheid receives non-exclusive worldwide distribution rights for several IDI assays mainly : IDI-Strep B(TM), IDI-MRSA(TM) and IDI-VRE(TM), which are configured for use with Cepheid's Smart Cycler(R). Moreover, Cepheid will get a license to apply some IDI's proprietary target sequences for its own assays to be performed on Cepheid's GeneXpert system.

"These new agreements increase the competitive advantage and strength of each company", says Jean-Pierre Gayral, President and Chief executive officer by interim. IDI and Cepheid have already demonstrated the capability of working together. They got a first FDA approved assay claiming culture replacement with IDI-Strep B(TM), and are expecting their second product, IDI- MRSA(TM), which will detect MRSA directly from clinical specimens. This product has just been filed with the regulatory agencies.

IDI is very confident that this new relationship with Cepheid will accelerate their successes on this competitive market.

INFECTIO DIAGNOSTIC INC.

CONTACT: Karina Jackson, Events Coordinator, Sales &Marketing, Office: (418) 681-4343, extension 234, Cellphone: (418) 284-2613



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES